Volumetric analysis of brain MRI allows for accurate and prompt rendering of the cortical surface. Here’s how we’re using it in three common neurological diseases.
This image-rich post profiles how we are using machine-learning algorithms to inform detection and delineation of pathological substrates on imaging studies in MS and epilepsy.
The novel therapy cut the rate of brain volume loss by nearly half relative to placebo in the notoriously treatment-refractory progressive form of multiple sclerosis. What’s ahead for ibudilast?
Randomized trials are the research standard, but they can’t address all clinical practice questions. So Cleveland Clinic is deriving real-world evidence from its large patient base to inform multiple sclerosis care.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
What’s the best disease-modifying treatment strategy for relapsing-remitting multiple sclerosis: escalation or hitting hard early? A new multicenter study will finally find out.
In multiple sclerosis, blocking the source — rather than the target — of excitotoxic glutamate is a more feasible therapeutic strategy for CNS protection. Neuroscientist Tara DeSilva, PhD, explains why, along with the research implications.
Stem cells show potential as disease-modifying and restorative therapy in a range of nervous system disorders, but they’re far from ready for prime time. An expert outlines the reasons why and the road ahead.
The new-generation S1P receptor modulator shows impressive effects on relapse rate and MRI lesion activity with no significant safety concerns. The trial’s lead investigator looks ahead to what’s next.
In this five-minute video, MS specialist Robert Bermel, MD, distills the essentials about how this new agent works, what makes it unique and what it achieved in pivotal trials.
The author of a new Lancet paper on progressive MS updates us on progress in the understanding and management of this traditionally largely untreatable stage of the disease.